A risk-enhancing factor that counts? (weighted — a single unconfirmed hs-CRP does not count until repeated) None on record
risk-borderline-no-enhancersNo one has reached this rule yetStatin optional — a CAC score or a confirmed hs-CRP can settle it
No clinician has signed off this rule yet. It reflects our reading of the guidelines cited below, which has not been independently checked.
Word for word, as generated for the example person below. Figures in the text are theirs.
Statin therapy can be considered, aiming for LDL-C below 100 mg/dL (and non-HDL-C below 130).
Your estimated 10-year PREVENT ASCVD risk is 4.0%, in the "borderline" 3%–5% range with no risk-enhancing factors on record. This is the band where the decision is genuinely a judgment call — a CAC score or hs-CRP (below) can settle it.
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Class 2a/2b
“Borderline risk, nothing else on file” — an illustrative profile, not a real user.
Asked after: 10-year risk 3% to under 5%
Cited by the recommendations above.
For practising clinicians. Endorse it, propose a change, or dispute it. We verify every reviewer before a review is shown, and a review stays attached to the version of the rule you saw — if the rule changes, the page says so. You'll be asked to declare any relevant interests; they're shown with your review.
Log in or create an account to submit a review. An account is how we tie a review to a person we can verify.
Runs in lib/engine/lipidPathway.ts as risk-borderline-no-enhancers.